INGN - NASDAQ
Inogen, Inc.
$5.98
-1.6%Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
At a Glance
Live SnapshotInogen, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Inogen, Inc. Cash Flow Statement
INGN • NASDAQ
| Inogen, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-22.7M | -35.9M | -102.4M | -83.8M | -6.3M | -5.8M | 21M | 51.8M | 21M | 20.5M | 11.6M | 6.8M | 25.4M | 564K | -2M | |
20.7M | 21M | 18.2M | 23.5M | 21.6M | 18.6M | 13.8M | 11.3M | 12.3M | 13.6M | 14M | 12.1M | 8.5M | 5M | 3.2M | |
-1.1M | -1.2M | -251K | 0.0 | 14.4M | -82K | 2.9M | -11.6M | 7.9M | 1M | 4.8M | 1.6M | -21.8M | 3K | 0.0 | |
8M | 7.4M | 7.4M | 12.3M | 10.9M | 8.2M | 9.1M | 12.8M | 9.6M | 7.3M | 3.6M | 1.5M | 230K | 60K | 144K | |
10.9M | 18.9M | 59.6M | 55.2M | 3M | 16.2M | 21.7M | 21.3M | 20.2M | 22.9M | 19.1M | 13.5M | 11.1M | 1.3M | 3.7M | |
(0.0) | (375K) | (0.0) | (0.0) | (0.0) | (0.0) | (239K) | (1.7M) | (1.3M) | (0.0) | (19K) | (2.1M) | (311K) | (37K) | (16K) | |
-26.9M | -4.4M | 14.3M | -44.7M | -20.1M | -31K | -27.9M | -25.6M | -10.6M | -34.3M | -14.9M | -19.7M | -10M | -2.9M | -3.2M | |
-11.2M | 5.9M | -3.2M | -37.5M | 23.6M | 37M | 40.6M | 60M | 60.5M | 31M | 38.2M | 15.7M | 13.5M | 4M | 1.9M | |
INVESTING ACTIVITIES | |||||||||||||||
-10.4M | (0.0) | -27M | -21.2M | -24.1M | -17.6M | -6.5M | -13M | -10.2M | -8M | -12.5M | -16.2M | -18.1M | -12.4M | -9M | |
(0.0) | (0.0) | -29.4M | (331K) | (153K) | (163K) | -70.4M | (350K) | -4.5M | -113K | (45K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-29.8M | -32.7M | -26.9M | (0.0) | -10M | -22.8M | -58.7M | -76.2M | -46.9M | -33.1M | -36.6M | -17K | (0.0) | (0.0) | (0.0) | |
14M | 35.5M | 24M | 10M | 19.3M | 14.5M | 91.4M | 63.5M | 37M | 28.8M | 19.8M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | -16.8M | 0.0 | 0.0 | 0.0 | 0.0 | 194K | 365K | 183K | 501K | -45K | -222K | -37K | -27K | 42K | |
-26.2M | -14M | -59.3M | -10.9M | -14.6M | -25.6M | -44.1M | -25M | -24.4M | -11.9M | -29.3M | -16.3M | -18.1M | -12.5M | -8.9M | |
FINANCING ACTIVITIES | |||||||||||||||
28.2M | 811K | 1.5M | 1.7M | 15.6M | 2.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 56.5M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -315K | -299K | -10.1M | 1.8M | -693K | 5.1M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -928K | -1.2M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-4M | -546K | -518K | -1.4M | -647K | -350K | 4.9M | 18.3M | 14M | 8M | 680K | 2.1M | 1.3M | 425K | 47K | |
24.2M | 265K | 960K | 380K | 15M | 2.1M | 4.9M | 18.3M | 14M | 7.7M | 381K | 43.9M | 3.1M | 19.7M | 5.2M | |
CASH FLOW SUMMARY | |||||||||||||||
846K | -281K | 67K | -481K | -426K | 486K | -62K | 373K | 34K | -76K | 33K | 0.0 | 0.0 | 0.0 | 0.0 | |
-12.4M | -8.1M | -61.5M | -48.5M | 23.6M | 13.9M | 1.4M | 53.7M | 50.1M | 26.7M | 9.3M | 43.3M | -1.6M | 11.2M | -1.9M | |
117.4M | 125.5M | 187M | 235.5M | 212M | 198M | 196.6M | 143M | 92.9M | 66.1M | 56.8M | 13.5M | 15.1M | 3.9M | 5.8M | |
105M | 117.4M | 125.5M | 187M | 235.5M | 212M | 198M | 196.6M | 143M | 92.9M | 66.1M | 56.8M | 13.5M | 15.1M | 3.9M | |
-21.6M | -11.2M | -29.8M | -58.8M | -302K | 19.7M | 34.1M | 47M | 50.3M | 23M | 25.7M | -540K | -4.7M | -8.4M | -7.1M |
SEC Filings
INGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 |
Related Guides
Continue your INGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.